ProCE Banner Activity

CodeBreaK100/101: Phase Ib Report of Safety and Efficacy of Sotorasib + Atezolizumab or Pembrolizumab in Patients With Pretreated KRAS G12C–Mutated NSCLC

Slideset Download
Cohort of patients with KRAS G12C–mutated NSCLC receiving sotorasib + atezolizumab or pembrolizumab had ORR of 29% and experienced high incidence of grade ≥3 TRAEs.

Released: August 16, 2022

Expiration: August 15, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Amgen, Inc.

Genentech, a member of the Roche Group

Merck Sharp & Dohme Corp.

Turning Point Therapeutics Inc